Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Study finds survival advantage for Hispanic lung cancer patients

A new analysis has found that Hispanic lung cancer patients seem to live longer than white or black patients. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study suggests that, as with several other types of cancer, certain yet-to-be-defined genetic and/or environmental factors put Hispanic patients at a survival advantage.

23 Apr 2012

Testosterone may help heart failure patients: Study

The researchers used testosterone patches and injections that improved the breathing and exercise abilities of people with heart failure, a chronic inability of the heart to pump enough blood to the rest of the body. Although most of the study participants were men, the researchers said the results would likely apply to women as well, through much smaller doses of testosterone.

18 Apr 2012

IMRT facilitates radiation dose escalation without compromising long-term morbidity for prostate cancer

In an analysis of three different types of radiation therapy used to treat localized prostate cancer, compared with conformal radiation therapy, intensity-modulated radiation therapy (IMRT) was associated with fewer diagnoses of gastrointestinal adverse effects, hip fractures, and receipt of additional cancer treatments but more erectile dysfunction, while proton therapy was associated with more gastrointestinal adverse effects than IMRT.

18 Apr 2012

IMRT better than CRT for treatment of localized prostate cancer

A treatment for localized prostate cancer known as Intensity Modulated Radiation Therapy (IMRT) is better than conventional conformal radiation therapy (CRT) for reducing certain side effects and preventing cancer recurrence, according to a study published in the April 18, 2012 issue of the Journal of the American Medical Association.

18 Apr 2012

New brain cancer vaccine with material from own tumors proves effective in clinical trial

A new brain cancer vaccine tailored to individual patients by using material from their own tumors has proven effective in a multicenter phase 2 clinical trial at extending their lives by several months or longer. The patients suffered from recurrent glioblastoma multiforme-which kills thousands of Americans every year.

18 Apr 2012

High intensity focused ultrasound to treat prostate cancer shows initial success

A new tumor treatment that involves heating it with highly focused ultrasound, may mean men with prostate tumors can be treated without an overnight stay in hospital and avoiding the distressing side effects associated with current therapies.

17 Apr 2012

U.S. spends more on cancer care, but gains time in return

A new analysis published in Health Affairs found that American cancer patients lived almost two years longer than those in 10 European countries -- leading the researchers to say that the additional expense is worth it.

12 Apr 2012

Botanical formula controls aggressive human prostate tumors in mice

A non-toxic, botanical formula controls aggressive human prostate tumors in mice, according to a peer-reviewed study in the The International Journal of Oncology. Researchers at Indiana University, Methodist Research Institute, showed the prostate formula significantly suppresses tumor growth in aggressive, hormone-refractory (androgen-independent) human prostate cancer cells.

11 Apr 2012

Peter Mac doctor receives grant to fight prostate cancer

The Victorian Minister for Health, the Hon David Davis, with the Richard Pratt Fellowships in Prostate Cancer Foundation and the Carlton Football Club, today announced Dr Helen Pearson as the 2012 recipient of the Richard Pratt Fellowship in Prostate Cancer Research.

10 Apr 2012

High cancer treatment costs in the US – are they worth it? Study explores

Healthcare in the United States is costlier than care in other countries. A new analysis suggests that the cost may be worth it at least when it comes to cancer care. Americans may pay more for cancer treatment, but they also live longer after diagnosis — getting a benefit that offsets their higher health expenses the study says.

10 Apr 2012

Low-dose spiral CT cost-effective in reducing lung cancer deaths

Lung cancer is the most lethal cancer in the United States. According to the National Cancer Institute, lung cancer causes more than 150,000 deaths annually and has a survival rate of 16 percent. More Americans die of lung cancer each year than of cervical, breast, colon and prostate cancers combined.

10 Apr 2012

Two CNVs may increase risk of aggressive prostate cancer

An international research team led by Weill Cornell Medical College investigators have discovered two inherited-genetic deletions in the human genome linked to development of aggressive prostate cancer.

10 Apr 2012

Study examines potential impact of policies to reduce inappropriate imaging for prostate cancer

In the current hyper-charged United States healthcare debate, the focus on lowering cost without compromising quality of care remains a priority. But according to a new study by researchers at NYU Langone Medical Center and colleagues, one common approach may have serious unintended consequences.

10 Apr 2012

New dietary supplement may arrest, lower rising PSA in men with recurrent prostate cancer

Preliminary findings from an FDA-approved clinical trial indicate that the experimental dietary supplement Prostate Health Cocktail (PHC) may arrest and in some cases lower rising PSA (Prostate Specific Antigen) in men with recurrent prostate cancer.

9 Apr 2012

Regeneron, Sanofi announce clinical and regulatory update for ZALTRAP

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the Biologics License Application (BLA) for the investigational agent ZALTRAP (aflibercept) concentrate for solution for infusion in combination with the irinotecan-fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-containing regimen.

6 Apr 2012

Cancer diagnosis associated with suicide, cardiovascular death

People who are diagnosed with cancer have a markedly increased risk of suicide and cardiovascular death during the period immediately after being given the diagnosis. This has been shown in a new study from Karolinska Institutet in Sweden, published in the prestigious scientific journal The New England Journal of Medicine.

6 Apr 2012

BIND announces data from BIND-014 Phase 1 trials on prostate cancer

Nanomedicine research at the David H. Koch Institute for Integrative Cancer Research at MIT funded by a $5 million grant from the Prostate Cancer Foundation (PCF) has delivered the first nanomedicine shown to successfully target prostate cancer cells and deliver docetaxel chemotherapy in high concentrations in Phase I clinical trials.

5 Apr 2012

Clinical data for cabozantinib to be presented at ASCO annual meeting

Exelixis, Inc. announced today that its lead compound, cabozantinib, will be the subject of nine separate data presentations at the upcoming Annual Meeting of the American Society of Clinical Oncology.

2 Apr 2012

WCMC receives SU2C-PCF Prostate Dream Team Translational Cancer Research Grant

An international team of investigators from centers in the United States and the United Kingdom, including Weill Cornell Medical College, have been awarded a grant for $10 million over a three-year period to study the molecular underpinnings of metastatic prostate cancer while creating a comprehensive testing system to optimize personalized treatments.

2 Apr 2012

Galeterone safe, effective for patients with CRPC

Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

2 Apr 2012